

Reply to: Consider the genetic and myopathic (**D** CrossMark background, familial occurrence, and alternative definitions of left ventricular hypertrabeculation/noncompaction

Sulafa K.M. Ali

Je would like to thank Prof. Stöllberger for her letter.

Regarding the echocardiographic (echo) definition of noncompaction cardiomyopathy (NCCM), we have shown that NCCM does involve the papillary muscles, especially the base of the muscle [1] (Fig. 3A and attached videos 1-4). Using echo, it is routine to visualize the papillary muscle and measure the non-compacted/compacted layer thickness ratio at its distal point.

In addition, our echo observations were confirmed by operative findings of friable papillary muscles documented by Chung et al. [2].

Stacey et al confirmed similar findings to ours of papillary muscle abnormalities by magnetic resonance imaging that predisposes to mitral regurgitation (MR) in patients with NCCM [3].

Regarding the comment on the left ventricle being thin walled, we could not find this description in our manuscript.

In patient number 4 with postoperative arrhythmia, there has been no documented stroke or embolism, and the child was discharged with hypoxic ischemic encephalopathy, then lost to follow up. We attribute ventricular arrhythmias to the NCCM.

We did not conduct genetic testing on this cohort, but none of them had skeletal myopathy. Some patients reported having familial myopathy and NCCM [4].

The controversies and pitfalls in the diagnosis of NCCM were extensively discussed, and there were many diagnostic criteria; however, echocardiography remains the most utilized method.

It has been well documented by us and others [4,5] that in NCCM, ejection fraction (EF) improves with or without treatment and then deteriorates later (relapses and remissions).

This feature is one of the few clinical signs that distinguishes NCCM from other types of cardiomyopathy.

The patients' echocardiographies were reviewed by two authors from Khartoum and Riyadh. Patients with EF below 45% were omitted from the study in order to exclude left ventricle/mitral valve annular dilatation as a cause of secondary MR. Those with EF > 45% are unlikely to have secondary MR, and as we are assuming a new

Disclosure: Author has nothing to disclose with regard to commercial support.

Available online 28 May 2015



P.O. Box 2925 Riyadh - 11461KSA Tel: +966 1 2520088 ext 40151 Fax: +966 1 2520718 Email: sha@sha.org.sa URL: www.sha.org.sa



1016-7315 © 2015 The Author. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Peer review under responsibility of King Saud University. URL: www.ksu.edu.sa http://dx.doi.org/10.1016/j.jsha.2015.05.007



Production and hosting by Elsevier

mechanism for MR, we needed to exclude other causes of this pathology.

Although we agree with Prof. Stöllberger that this disease needs to be more accurately defined, we have no doubt that it causes distinct echo changes on the mitral valve leading to MR.

References

- [1] Ali SK, Abu-Sulaiman R, Agouba RB. Noncompaction cardiomyopathy: A new mechanism for mitral regurgitation with distinct clinical, echocardiographic features and pathological correlations. J Saudi Heart Assoc 2015;27(2):71–8.
- [2] Chung JW, Lee SJ, Lee JH, Chin JY, Lee HJ, Lee CJ, et al. Isolated left ventricular noncompaction cardiomyopathy accompanied by severe mitral regurgitation. Korean Circ J 2009;39(11):494–8.
- [3] Stacey RB, Haag J, Hall ME, McLeod G, Upadhya B, Hundley WG, et al. Mitral regurgitation in left ventricular noncompaction cardiomyopathy assessed by cardiac MRI. J Heart Valve Dis 2014;23(5):591–7.
- [4] Ali SK. Unique features of non-compaction of the ventricular myocardium in Arab and African patients. Cardiovasc J Afr 2008;19(5):241–5.
- [5] Pignatelli RH, McMahon CJ, Dreyer WJ, Denfield SW, Price J, Belmont JW, et al. Clinical characterization of left ventricular noncompaction in children: a relatively common form of cardiomyopathy. Circulation 2003; 108(21):2672–8.